2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

Simon, Thorsten; Hero, Barbara; Schulte, Johannes H.; Deubzer, Hedwig E.; Hundsdoerfer, Patrick; Schweinitz, Dietrich von; Fuchs, Jörg; Schmidt, Matthias; Prasad, Vikas; Krug, Barbara; Timmermann, Beate; Leuschner, Ivo; Fischer, Matthias; Langer, Thor﻿s﻿ten; Astrahantseff, Kathy; Berthold, Frank; Lode, Holger N.; Eggert, Angelika

doi:10.1055/s-0043-103086

Cited by 92 publications

(86 citation statements)

References 207 publications

(252 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Certain patients with malignant tumors were treated with chemotherapy, which consisted of different combinations of vincristine, cisplatin, etoposide, cyclophosphamide, and carboplatin (13)(14)(15). Additionally, some patients gave up treatment after the diagnosis.…”

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Lin

Chen

et al. 2018

Iran J Pediatr

View full text Add to dashboard Cite

Background: The true incidence of peripheral neuroblastic tumors (PNTs) in children is unknown. This study aims to review and analyze clinical data on the diagnosis and management of pediatric PNTs. Methods: Between 2007 and 2016, a total of 43 pediatric patients admitted to our institute with PNTs were reviewed. Results: The series comprised of 23 males and 20 females with a median age of 1.2 years old. Among the 43 PNTs, 26 tumors originated from the abdomen, 13 from the thorax and four from other primary sites. A total of 16 tumors were identified in routine examinations. Abdominal pain and distension were the main clinical manifestations of abdominal PNTs, while coughing was the most frequent presenting symptom of thoracic PNTs. Elevated vanillylmandelic acid level in the urine over 24 hours was observed in 18 neuroblastoma cases and three ganglioneuroblastoma cases. Neuroblastoma was the most common type of PNT that was reported in 30 (69.8%) patients, followed by ganglioneuroblastoma, which was diagnosed in 11 (25.6%) patients. Only 2 (4.6%) patients were diagnosed with ganglioneuroma. A total of 12 cases were stage, six cases were stage II, three cases were stage III, 18 cases were stage IV, and four cases were stage IVs. The overall two year survival rate was 62.9%, which was related to pathological type, Shimada classification, stage, and primary site. Conclusions: Pediatric PNTs have different clinical characteristics and outcomes. Imaging and laboratory data may be useful for the differentiation of PNTs. This study will help pediatric surgeons be aware of the possible manifestations of PNTs in children.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Lin

Chen

et al. 2018

Iran J Pediatr

View full text Add to dashboard Cite

show abstract

“…When we evaluated neuroblastoma as a separate category, we found that ALL and neuroblastoma patients had the same risk of developing PFN (Table 2). A possible reason for this is that current neuroblastoma protocols include intensive chemotherapy followed by autologous SCT [17].…”

Section: Discussionmentioning

confidence: 99%

Febrile Neutropenia in Children: Etiologies, Outcomes, and Risk Factors with Prolonged Fever

Alali¹,

David²,

Ham³

et al. 2020

OBM Transplantation

View full text Add to dashboard Cite

show abstract

“…Statistical assessments: dispersion in the results obtained for a subgroup of patients with a common clinical diagnosis, belonging to different hospitals where the diagnosis studies were undertaken European repositories for NB and DIPG. We aim to impact current clinical guidelines [40]. PRIMAGE is designed to have a major impact on improving the disease management of malignant solid tumours.…”

Section: Reproducibilitymentioning

confidence: 99%

PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers

et al. 2020

Self Cite

View full text Add to dashboard Cite

PRIMAGE is one of the largest and more ambitious research projects dealing with medical imaging, artificial intelligence and cancer treatment in children. It is a 4-year European Commission-financed project that has 16 European partners in the consortium, including the European Society for Paediatric Oncology, two imaging biobanks, and three prominent European paediatric oncology units. The project is constructed as an observational in silico study involving high-quality anonymised datasets (imaging, clinical, molecular, and genetics) for the training and validation of machine learning and multiscale algorithms. The open cloud-based platform will offer precise clinical assistance for phenotyping (diagnosis), treatment allocation (prediction), and patient endpoints (prognosis), based on the use of imaging biomarkers, tumour growth simulation, advanced visualisation of confidence scores, and machine-learning approaches. The decision support prototype will be constructed and validated on two paediatric cancers: neuroblastoma and diffuse intrinsic pontine glioma. External validation will be performed on data recruited from independent collaborative centres. Final results will be available for the scientific community at the end of the project, and ready for translation to other malignant solid tumours.

show abstract

2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors

Cited by 92 publications

References 207 publications

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Clinical Characteristics of Peripheral Neuroblastic Tumors in Children: A Single-Center Experience of 43 Cases

Febrile Neutropenia in Children: Etiologies, Outcomes, and Risk Factors with Prolonged Fever

PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers

Contact Info

Product

Resources

About